Literature DB >> 22892365

The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series.

Kevin Peterson1, Jean Ruelle, Marc Vekemans, Frederick P Siegal, Jane R Deayton, Robert Colebunders.   

Abstract

We describe five patients with HIV-2 infection (four antiretroviral-experienced and one antiretroviral-naive) treated with a regimen containing raltegravir. All responded to treatment as demonstrated by viral load and CD4(+) T-cell count monitoring. Our series confirms the clinical effectiveness of raltegravir in HIV-2-infected patients when given with other antiretrovirals to which the virus is susceptible.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22892365     DOI： 10.3851/IMP2303

Source DB:  PubMed          Journal:  Antivir Ther        ISSN： 1359-6535


  6 in total

1.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  In Vitro Antiviral Activity of Cabotegravir against HIV-2.

Authors:  Robert A Smith; Vincent H Wu; Christopher G Zavala; Dana N Raugi; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

3.  Comparing Treatment Outcomes of Antiretroviral Therapy in HIV-1 and HIV-2 Infected Patients, in Bamako, Mali.

Authors:  Aboubacar Alassane Oumar; Yacouba Cissoko; Issa Konaté; Adam Kane; Jean Paul Dembélé; Mamadou Cissé; Robert Leo Murphy; Jean Cyr Yombi; Moussa Seydi; Sounkalo Dao; Mamoudou Maiga
Journal:  Curr Find Infect Dis       Date:  2018-11-26

4.  In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.

Authors:  Robert A Smith; Dana N Raugi; Charlotte Pan; Papa Salif Sow; Moussa Seydi; James I Mullins; Geoffrey S Gottlieb
Journal:  Retrovirology       Date:  2015-02-05       Impact factor: 4.602

Review 5.  Antiretroviral therapy response among HIV-2 infected patients: a systematic review.

Authors:  Didier K Ekouevi; Boris K Tchounga; Patrick A Coffie; Joseph Tegbe; Alexandra M Anderson; Geoffrey S Gottlieb; Marco Vitoria; François Dabis; Serge P Eholie
Journal:  BMC Infect Dis       Date:  2014-08-26       Impact factor: 3.090

6.  First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).

Authors:  Sophie Matheron; Diane Descamps; Sebastien Gallien; Amel Besseghir; Pierre Sellier; Laurent Blum; Emmanuel Mortier; Charlotte Charpentier; Roland Tubiana; Florence Damond; Gilles Peytavin; Diane Ponscarme; Fideline Collin; Francoise Brun-Vezinet; Genevieve Chene
Journal:  Clin Infect Dis       Date:  2018-09-28       Impact factor: 9.079
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.